# OnCo record paper-trident-1-repotrectinib-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-trident-1-repotrectinib-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-trident-1-repotrectinib-nejm-2024" ;
  schema:name "TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer"@en ;
  schema:description "The next-generation ROS1 and TRK inhibitor repotrectinib shrank tumours in almost four in five untreated patients with ROS1-positive lung cancer, kept the disease under control for nearly three years, and worked in about four in ten patients after crizotinib including those with the resistant G2032R mutation."@en ;
  schema:url <https://onco.cc/key-papers/paper-trident-1-repotrectinib-nejm-2024/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2302299>, <https://pubmed.ncbi.nlm.nih.gov/38197815/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2302299> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Drilon A, Camidge DR, Lin JJ, et al." ;
  onco:cancers <https://onco.cc/cancers/ntrk-fusion-nsclc/>, <https://onco.cc/cancers/ros1-positive-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/repotrectinib/> ;
  onco:journals <https://onco.cc/journals/nejm/> .